Product Name: WNK1 (379-385) pS382
Product Number: PE-04ALK99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: WNK1 (379-385) pS382

Product Use: Services as a blocking peptide for use with the WNK1-pS382 rabbit polyclonal antibody (Cat. No.: AB-PK855) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. S382 phosphorylation sttimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: FAK-pS-VIG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 975.05 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: WNK1 - pS382 phosphosite-specific antibody (Cat. No.: AB-PK855)

Scientific Background: Wnk1 (PRKWNK1) is a protein-serine/threonine kinase of the Other group and Wnk family. It is involved in electrolyte homeostasis, cell survival, cell signalling, and cell proliferation. It is activated by hypertonicity. The activation requires autophosphorylation of S382. Phosphorylation of S378 also promotes increased phosphotransferase activity. Wnk1 can activate sodium-coupled chloride cotransporters, and inhibit potassium-coupled chloride cotransporters. Proteins activated by Wnk1 include SCNN1A, SCNN1B, SCNN1D and SGK1 while an inhibited protein is Wnk4 (via phosphorylation of Wnk4 or an associated complex of a Wnk1 autoinhibitory domain bound to Wnk4). Wnk4 inhibition could modulate, via phosphorylation, a thiazide-sensitive NaCl cotransporter transporter (specifically SLC12A3). Wnk1 has also been proposed to modulate NEDD4L phosphorylation, and have an effect on actin cytoskeleton rearrangement. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.